The Day In Review: Amgen (Jobs) Rises On Speculation Over Patent Suit

January 22, 2007 – Amgen rose on predictions it will win a patent suit against Roche and its Cera drug that threatens the dominance of Amgen in the EPO market; PharmAthene will be acquired by Healthcare Acquisition in a deal worth $93 million; Infinity and MedImmune released positive data from a trial of their heat shock protein 90 inhibitor; AstraZeneca will invest $100 million in its Boston-area facility; Geron exercised an option to use a proprietary manufacturing technology from MaxCyte; Cell Genesys reported follow-up data from a Phase II trial of GVAX, a cancer vaccine; Roche reported that XELOX was just as effective as FOLFOX-4 against colorectal cancer; Molecular Insight set its IPO terms; Halozyme reported positive data on the use of Enhanze with large protein molecule drugs; Discovery Labs and the FDA have settled on a path for final approval of Surfaxin; and Pfizer announced a 7,500 employee layoff. The Centient Biotech 200™ fell 12 points to just under 4100, a loss of .12%. More details...

Back to news